Anafranil: Restoring Balance in Severe OCD Treatment
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.89 | $53.50 (0%) | 🛒 Add to cart |
| 90 | $0.81 | $80.24 $72.67 (9%) | 🛒 Add to cart |
| 120 | $0.77 | $106.99 $91.85 (14%) | 🛒 Add to cart |
| 180 | $0.72 | $160.49 $130.21 (19%) | 🛒 Add to cart |
| 270 | $0.69 | $240.73 $186.73 (22%) | 🛒 Add to cart |
| 360 | $0.68
Best per pill | $320.97 $244.26 (24%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.88 | $56.52 (0%) | 🛒 Add to cart |
| 60 | $1.48 | $113.05 $88.82 (21%) | 🛒 Add to cart |
| 90 | $1.36 | $169.57 $122.13 (28%) | 🛒 Add to cart |
| 120 | $1.29 | $226.09 $154.43 (32%) | 🛒 Add to cart |
| 180 | $1.23 | $339.14 $221.05 (35%) | 🛒 Add to cart |
| 270 | $1.18 | $508.71 $317.94 (37%) | 🛒 Add to cart |
| 360 | $1.16
Best per pill | $678.28 $416.86 (39%) | 🛒 Add to cart |
| Product dosage: 75mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.62 | $78.73 (0%) | 🛒 Add to cart |
| 60 | $2.10 | $157.46 $126.17 (20%) | 🛒 Add to cart |
| 90 | $1.93 | $236.19 $173.61 (26%) | 🛒 Add to cart |
| 120 | $1.85 | $314.92 $222.06 (29%) | 🛒 Add to cart |
| 180 | $1.77 | $472.37 $317.94 (33%) | 🛒 Add to cart |
| 270 | $1.71
Best per pill | $708.56 $461.27 (35%) | 🛒 Add to cart |
Synonyms | |||
Anafranil (clomipramine hydrochloride) is a tricyclic antidepressant (TCA) with potent serotonin reuptake inhibition properties, specifically indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD) when first-line treatments prove inadequate. It represents one of the most rigorously studied pharmacological interventions for moderate to severe OCD, offering a mechanism of action that directly targets the neurochemical imbalances associated with the disorder. Its efficacy is well-documented in numerous clinical trials, establishing it as a cornerstone option for specialists managing complex OCD presentations.
Features
- Active ingredient: Clomipramine hydrochloride
- Available in 10 mg, 25 mg, and 50 mg film-coated tablets
- Potent serotonin reuptake inhibitor (SRI) with secondary noradrenergic effects
- FDA-approved for the treatment of obsessions and compulsions in OCD
- Bioavailability of approximately 50% after oral administration
- Peak plasma concentrations reached within 2–6 hours post-dose
- Extensive hepatic metabolism via cytochrome P450 enzymes (primarily CYP2D6 and CYP3A4)
- Elimination half-life of approximately 19–37 hours
Benefits
- Significantly reduces the frequency and intensity of obsessive thoughts and compulsive behaviors
- Improves overall daily functioning and quality of life in patients with severe OCD
- Provides an evidence-based alternative when SSRIs are ineffective or poorly tolerated
- Demonstrates robust efficacy in treatment-resistant cases through its dual neurotransmitter action
- Supports long-term maintenance therapy with established dosing protocols
- May alleviate comorbid depressive symptoms often associated with chronic OCD
Common use
Anafranil is primarily prescribed for the treatment of Obsessive-Compulsive Disorder in adults and children aged 10 years and older. It is particularly valuable in cases where selective serotonin reuptake inhibitors (SSRIs) have provided insufficient symptom relief or caused unacceptable side effects. The medication may also be used off-label for severe panic disorder, chronic pain syndromes, and treatment-resistant depression, though these applications require careful specialist supervision. Clinical response typically emerges within 2–4 weeks of achieving therapeutic dosing, with maximum benefits often requiring 8–12 weeks of continuous treatment.
Dosage and direction
Initial dosage for adults typically begins at 25 mg daily, gradually increased to 100 mg daily during the first two weeks. The therapeutic range generally falls between 150–250 mg daily, divided into two or three doses. For elderly patients or those with hepatic impairment, initial dosing should not exceed 20–30 mg daily, with cautious titration. Pediatric patients (ages 10–17) should start at 25 mg daily, gradually increasing to a maximum of 200 mg daily or 3 mg/kg daily, whichever is smaller. All dosage adjustments must be supervised by a physician, with regular monitoring of therapeutic response and side effects. Tablets should be swallowed whole with water, preferably with food to minimize gastrointestinal discomfort.
Precautions
Patients should be monitored for emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania. Closely observe patients for clinical worsening and suicide risk, especially during initial treatment and dosage adjustments. Use with caution in patients with cardiovascular disorders due to potential orthostatic hypotension, tachycardia, and conduction abnormalities. Regular ECG monitoring is recommended in patients with pre-existing cardiac conditions. Hepatic and renal function should be assessed periodically during long-term therapy. Abrupt discontinuation should be avoided due to risk of withdrawal symptoms including nausea, headache, and malaise.
Contraindications
Hypersensitivity to clomipramine or other tricyclic antidepressants; concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy; recent myocardial infarction; any degree of heart block or other cardiac conduction abnormalities; severe liver impairment; narrow-angle glaucoma; urinary retention. Not recommended during the acute recovery phase following myocardial infarction.
Possible side effects
Common (≥1/10): Dry mouth, sweating, constipation, nausea, dizziness, somnolence, tremor, blurred vision, weight gain, sexual dysfunction.
Less common (1/100 to 1/10): Orthostatic hypotension, tachycardia, palpitations, confusion, headache, fatigue, increased appetite, urinary retention.
Rare (<1/1000): Seizures, agranulocytosis, hepatitis, neuroleptic malignant syndrome, hyponatremia, angle-closure glaucoma.
Cardiac effects including QT prolongation may occur, particularly at higher doses or in susceptible individuals.
Drug interaction
MAOIs: Risk of serotonin syndrome and hypertensive crisis.
SSRIs/SNRIs: Additive serotonergic effects increasing toxicity risk.
CYP2D6 inhibitors (quinidine, fluoxetine): Increased clomipramine levels.
Anticholinergic agents: Enhanced anticholinergic effects.
Sympathomimetics: Potentiated pressor effects.
Warfarin: Altered anticoagulant effect requiring INR monitoring.
Antihypertensives: Possible reduced antihypertensive efficacy.
CNS depressants: Enhanced sedative effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Patients should maintain a consistent dosing routine and use pill organizers or reminders if forgetfulness becomes problematic.
Overdose
Symptoms may include severe drowsiness, agitation, confusion, hallucinations, tachycardia, hypotension, convulsions, coma, and cardiac arrhythmias. Management requires immediate medical attention with gastric lavage if presented early, activated charcoal, and comprehensive supportive care including cardiac monitoring for at least 72 hours. Physostigmine may be considered for central anticholinergic effects in severe cases. There is no specific antidote; treatment is symptomatic and supportive.
Storage
Store at room temperature (15–30°C/59–86°F) in the original container, protected from light and moisture. Keep tightly closed and out of reach of children and pets. Do not use after the expiration date printed on the packaging. Dispose of unused medication through take-back programs or according to local regulations to prevent environmental contamination.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Treatment decisions must be made by qualified healthcare professionals based on individual patient assessment. The prescribing physician should be consulted for complete information regarding indications, contraindications, warnings, precautions, and adverse effects. Never adjust dosage or discontinue medication without medical supervision.
Reviews
Clinical studies demonstrate response rates of 50–70% in OCD patients treated with adequate doses of Anafranil for 10–12 weeks. Many treatment-resistant patients report significant improvement in quality of life and functional capacity. However, side effects, particularly anticholinergic effects and weight gain, remain treatment-limiting factors for some individuals. Long-term maintenance therapy shows sustained efficacy in preventing relapse when properly monitored. Patient experiences vary considerably, emphasizing the need for personalized treatment approaches under specialist supervision.